Dr. Prashant Mehta

Dr Prashant Mehta, a noted Medical Oncologist and a Bone marrow transplant physician, obtained his DM fellowship in Medical oncology and BMT from the apex institute of the country, AIIMS , New Delhi .
He is also an alumnus of the prestigious Maulana Azad Medical College, New Delhi and was a proud recipient of Meghna Krishna Baweja award for all round excellence at MAMC.
He has received the prestigious Prof GS Bhattacharya award for Best all rounder oncologist in India in the year 2021, from Indian Cooperative Oncology Network (ICON).

His primary areas of focus are Acute Leukemia and Lymphoma in children and adults, Bone marrow transplantation, including haploidentical transplants and reduced toxicity transplantation.
He works as Clinical lead for Lymphoid neoplasms, Haploidentical BMT in adults and children , Lung cancer , gynecological cancer , sarcoma and melanoma.
He has been Prinicipal Investigator for more than 20 clinical trials and is a founder member of ' Science and Cost ' association which works on solutions to improve access to cancer care in India using scientific strategies. He has more than 60 publications in various national and international journals, including book chapters . He is also the Joint editor and web editor for our national oncology journal IJMPO .
Dr Prashant Mehta is credited with the first Bone marrow transplant, first Total Body irradiation based transplant and first MUD transplant in Faridabad region.
His randomized study on dose of Cytarabine during consolidation in Acute Myeloid Leukemia, was selected for oral presentation at ESMO Asia, Singapore. Apart from this he is has a notable presence in various national and international scientific societies.
He is leading the cellular therapy program at Amrita as well as working on making CAR- T cell therapies accessible in India by working in close collaboration with researchers and scientists in India as well as outside. He is skilled in immunotherapy and precision oncology and employs these effectively in suitable scenarios.

Dr Prashant believes that the goal of treatment apart from cure and disease control is happiness and quality of life. He believes in transparency between patient, family and treating Doctor pertaining all aspects of treatment.
The treatment of cancer is complex and associated with different forms of distress for family and patient. Dr Prashant Mehta approaches a patient and disease with the above understanding and hopes to provide comfort and dignity to the patient and the family in difficult situations.
 

MBBS -Maulana Azad Medical College (MAMC, Delhi)-2006

MD - Medicine (Lady Hardinge Medical College, Delhi)-2010

DM - Medical Oncology , All India Institute of Medical Sciences (AIIMS, Delhi)-2014

Visiting Physician fellowship in BMT/Cellular therapy- Fred Hutchinson Cancer research Center, Seattle USA -2016

• Lymphoma
•  Acute Lymphoblastic Leukaemia
•  Multiple Myeloma
•  T cell replete
• Haploidentical BMT
• Reduced toxicity conditioning Chemotherapy
• Acute Myeloid Leukemia in children and Adults 
• Management of Chronic Myeloid Leukemia in accelerated phase or blast crisis 
• Precision oncology, targeted therapy, immunotherapy 
• Molecular Oncology 
• Lung cancer
•  Sarcomas
• Ovarian cancer
• Management of NK/T cell Lymphoma 
• Metronomic treatment of Advanced Head and neck cancer 

• Recipient of the Prestigious ‘Professor GS Bhattacharya Memorial Award’ for Best All rounder Oncologist in India conferred by the Indian Cooperative Oncology Network (ICON) in 2021
• Recipient of the prestigious Meghna Krishna Baweja Memorial award 2001-2002 for all round excellence in 1st Professional MBBS (2001-2002) at Maulana Azad Medical College, Delhi 
• Founder Member of Science and Cost Cancer Consortium which is a group of oncologists aiming to improve access to cancer care by utilising scientific principles and drug pharmacokinetics

• Mehta P, Arora R. Clofarabine-based conditioning for T-cell replete haploidentical hematopoietic stem cell transplant for relapsed/refractory acute leukemia using peripheral blood stem cell grafts and post-transplantation cyclophosphamide. Cancer Res Stat Treat [serial online] 2020 [cited 2022 Jul 28];3:614-7. Available from: https://www.crstonline.com/text.asp?2020/3/3/614/295513

• Mehta P et al. Utility of Serial Measurement of Serum C-Reactive Protein and Procalcitonin in Patients Undergoing HSCT https://tct.confex.com/tct/2020/meetingapp.cgi/Paper/14986
  
   
• Prashant Mehta, Rahul Arora, Swati Pabbi. Feasibility of Cyclosporine a Instead of Tacrolimus after Haploidentical Transplantation Using PBSC Grafts with Post-Transplant Cyclophosphamide for Hematological MalignanciesBiology of Blood and Marrow Transplantation,Volume 26, Issue 3, Supplement,2020,Page S279, https://doi.org/10.1016/j.bbmt.2019.12.545.
  
   
• Mehta P, Bothra SJ. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23. PMID: 34844716.
  
   
• Mehta P et al."Oncotype DX: Where Does It Stand in India?." Journal of Global Oncology, 5, pp. 1–2 © 2019 by American Society of Clinical Oncology
   
• Patel A, Mehta P, Tannock IF, Srivastava P, et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020;6:382-386. doi:10.1200/JGO.19.00341

• Bahl A, Talwar V, Sirohi B, Mehta P, Arya D, Shrivastava G, Dahiya A and Pavithran K (2020) Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). Front. Oncol. 10:964. doi: 10.3389/fonc.2020.00964 .
• Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal cancer chemotherapy  during COVID-19 pandemic. Indian J Med Paediatr  Oncol
  
   
• Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Patel A, Bhethanabhotla S, Batra A, Pramanik R, Gupta VG, Das CK, Mahindru S. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India?. Indian J Med Paediatr Oncol 2020;41:149-52
  
   
• Mahindru S, Das CK, Patel A, Mehta P, Biswas B, Batra A, Bandhopadhyay A. Cancer surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian J Med Paediatr Oncol 2020;41:144-8
  
   
• Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, Patel A, Batra A, Mehta P. Systemic treatment of gastroesophageal cancer during SARS-CoV2. Indian J Med Paediatr Oncol 2020;41:141-3
  
   
• Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bhethanbhotla S, Biswas B, Batra A, Gupta VG, Das CK, Mahendru S. Management of head-and-neck cancer during COVID-19 crisis: A medical oncology perspective. Indian J Med Paediatr Oncol 2020;41:153-5
  
   
• Patel A, Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, Gangulay S, Gupta VG. Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India. Indian J Med Paediatr Oncol 2020;41:132-4
  
   
• Batra A, Mehta P, Patel A, Bhethanabhotla S, Biswas B, Pramanik R, Das CK. Breast cancer treatment during the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:135-7
  
   
• Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Pramanik R, Bhethanabhotla S, Gupta VG. How I treat epithelial ovarian cancer during COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:138-40
  
   
• Srivastava P, Tilak T V, Patel A, Das CK, Biswas B, Mahindru S, Pramanik R, Ghosh J, Mehta P. Advisory for cancer patients during the COVIDpandemic. Cancer Res Stat Treat 2020;3, Suppl S1:145-8
  
   
• Das CK, Mehta P et al. Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India.https://meetinglibrary.asco.org/record/186667/abstract
  
   
• Mehta P, Parikh P, Aggarwal S, Batra A, Patel A, Kulkarni P, et al. Has India met this enemy before? From an eternal optimist’s perspective: SARS-CoV-2. Indian J Med Sci 2020;72(1):8-12.

• Parikh PM, Mehta P, Krishna Mohan MVT, Bhattacharya G S, Govind Babu K. “Serious Adverse Events” faced by clinical trials: Impact of the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:127-31

• Mehta P, Bhajoni PS, Mehta SP. Fighting cancer through an informed society. J Soc Health Diabetes 2016 [cited 2017 Jan 31];4:57-66
  
   
• Mehta P, Raina V, Kumar L, et al. Nasal NK-T cell lymphoma: 10-year experience of a single institute in India. ; J Clin Oncol 32, 2014 (suppl; abstr e19536) .

• Ajay Gogia, Prashant Mehta, Raja Pramanik, Rajive Kumar. Isolated Breast Relapse Mimicking Breast Cancer in Elderly Patient with Acute Lymphoblastic Leukemia;Turk J Hematol 2014;31:203-204 .

• Ajay Gogia, Prashant Mehta,Ritu Gupta et al.Chronic lymphocytic leukemia with massive ascites: An unusual presenting manifestation; South Asian J Cancer. 2014 Oct- Dec; 3(4): 235–236. 

• Gogia A, Raina V, Kumar L, Sharma A, Mehta P, Sharma MC. Diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia: A single center experience. South Asian J Cancer 2014;3:186 .

• Gogia A, Mehta P, et al.Cryptococcal meningitis in chronic lymphocytic leukemia; Indian J Cancer. 2013 Oct-Dec;50(4):301 

• Ankur Bahl, Prashant Mehta, and Vinod Raina. Severe Eosinophilia in Metastatic Carcinoma Breast: A Rare Paraneoplastic Phenomenon; Eur J clin med onc ,sept 2012.

• Mehta P, Rohtagi A, Sharma S K. et al. A case report of Rheumatoid Arthritis presenting with Right Heart Failure due to Pulmonary Artery Hypertension; Max Med J; vol 4,1, 2009, 7-9. 

• Mehta P, Rohtagi A, Sharma S K. et al. A case of Mixed connective Tissue Disease presenting with alopecia Ind. J. Clin Pr, Vol. 19, 9, 2009; 37-39.

• Mehta P, Raina V, Kumar L, et al. Nasal NK-T cell lymphoma: 10-year experience of a single institute in India. ; under consideration in National medical journal of India

• MEHTA, Prashant; BHAJONI, Pranjit Santonu; MEHTA, Swati Pabbi. Response to afatinib, after gefitinib and erlotinib, in a patient with advanced adenocarcinoma of lung with brain metastasis: A case report. International Journal of Molecular and Immuno Oncology, [S.l.], v. 2, n. 1, p. 22-24, jan. 2017.
   
• PARIKH, Purvish M, Mehta P. et al. Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care. International Journal of Molecular and Immuno Oncology, [S.l.], v. 2, n. 2, p. 47-57, jun. 2017